GRADE & PURITYAnimal Free?Animal-free — produced without animal-derived components to reduce contamination risk. Use in biomanufacturing and culture avoiding animal-origin material.Carrier Free?Carrier-free — supplied without added carrier protein/stabilizer. Use when carriers (e.g. BSA) would interfere with conjugation or sensitive assays.Bioactive?Bioactive grade — verified to retain biological activity in functional assays. Use when the molecule must be functionally active, not just pure.ActiBioPure™?ActiBioPure™ — Aladdin's premier line for bioactive and recombinant products. Use when both high purity and preserved biological activity are required.His Tag?His tag grade — recombinant protein bearing a His tag for affinity purification/detection. Use to purify, immobilize, or detect the tagged protein.≥95%(SDS-PAGE)
Expression System
HEK293
Accession #
Q9NR61
Protein Tag
C-His
Expression system
HEK293
Endotoxin Concentration
<1.0 EU/μg
Bioactivity
1. Immobilized Recombinant Human DLL4 Protein (rp181238) at 5.0 μg/mL can bind Recombinant Human Notch-1 Protein (rp183726) with the EC50 of 26.54 ng/mL. 2. Immobilized Recombinant Human DLL4 Protein (rp181238) at 1.0 μg/mL can bind Navicixizumab (anti-DLL4) (Ab176598) with the EC50 of 69.79 ng/mL.
Animal Free,Carrier Free,Bioactive,ActiBioPure™,His-Tag,≥95%(SDS-PAGE) ActiBioPure™,Animal Free,Bioactive,Carrier Free,His Tag for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
🌡
Storage & shipping
Store at -20°C,Avoid repeated freezing and thawing Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
📋
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
📚
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Descripción general
Protein Function: Delta-like protein 4 (DLL4) is a type I membrane protein belonging to the Delta/Serrate/Lag2 (DSL) family of Notch ligands. Notch signaling is an evolutionarily conserved pathway that controls cell fate and is required in multiple developmental processes including vascular development, hematopoiesis, somatogenesis, myogenesis, and neurogenesis. Dysregulation in the Notch pathway is associated with various human diseases. In mammals, four Notch homologs (Notch 1 to 4) and five ligands (DLL 1, 3 and 4, Jagged 1 and 2) have been identified. Notch ligands are transmembrane proteins with a DSL motif necessary for Notch binding, tandem EGF repeats, a transmembrane region and a short intracellular domain (ICD). Notch ligands are categorized into two subfamilies based on the presence of an extracellular cysteine-rich domain and insertions that interrupt some EGF repeats in the Jagged but not the Delta ligand family. Interactions of Notch receptors with their ligands result in reciprocal regulated intramembrane proteolysis (RIP). RIP is a mechanism for transmembrane signal transduction that involves the sequential processing by a disintegrin metalloprotease (ADAM) and then by presenilin/ gamma secretase, resulting in shedding of the extracellular domains and the generation of the soluble ICD signaling fragments, respectively. The Notch ICD translocates to the nucleus and interacts with transcriptional coactivators, resulting in the transcription of target genes. The ICDs of the Notch ligands have also been shown to translocate to the nucleus where they may have a signaling function. DLL4 is expressed highly and selectively within the arterial endothelium and has been shown to function as a ligand for Notch 1 and Notch 4. Human and mouse DLL4 share 86% amino acid sequence identity.
1. Immobilized Recombinant Human DLL4 Protein (rp181238) at 5.0 μg/mL can bind Recombinant Human Notch-1 Protein (rp183726) with the EC50 of 26.54 ng/mL. 2. Immobilized Recombinant Human DLL4 Protein (rp181238) at 1.0 μg/mL can bind Navicixizumab (anti-DLL4) (Ab176598) with the EC50 of 69.79 ng/mL.
55.7-64.8 kDa, under reducing condition; 56.6-68.7 kDa, under non-reducing condition
Tipo de molécula
Protein
Almacenamiento y envío
Forma
Lyophilized
Reconstitución
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute at 0.1 mg/mL in sterile distilled water. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Condiciones de almacenamiento de almacenamiento
Store at -20°C,Avoid repeated freezing and thawing
Enviado en
Ice chest + Ice pads
Estabilidad y almacenamiento
Store at -20°C for 1 year. Avoid freeze / thaw cycle.
Imágenes
Recombinant Human DLL4 Protein (rp181238) - ELISA Immobilized Recombinant Human DLL4 Protein (rp181238) at 1.0 μg/mL can bind Navicixizumab (anti-DLL4) (Ab176598) with the EC
₅₀
of 69.79 ng/mL.
Recombinant Human DLL4 Protein (rp181238) - SDS-PAGE 2 μg/lane of Recombinant Human DLL4 Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 55.7-64.8 kDa under reducing conditions and 56.6-68.7 kDa under non-reducing conditions.
Recombinant Human DLL4 Protein (rp181238) - Binding Activity Immobilized Recombinant Human DLL4 Protein (rp181238) at 5.0 μg/mL can bind Recombinant Human Notch-1 Protein (rp183726) with the EC₅₀ of 26.54 ng/mL.
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.
Shall we send you a message when we have discounts available?
Remind me later
Thank you! Please check your email inbox to confirm.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
ZJ24F0606470
